Frontlight ResearchEarly access
TerminatedPhase 3
A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy
Key facts
- Who runs it
- Jiangsu HengRui Medicine Co., Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 3
- People taking part
- 391 people enrolled
- Started
- 1 Nov 2021
- Ended
- 6 Sept 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- SHR3680
- Placebo
- Record updated
- 3 April 2026
- Why it stopped
- Due to the adjustment of the sponsor's development plan, after discussion with leading PI, sponsor has decided to terminate this study.
Who can take part
- Age
- 18 years and older
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Age of ≥ 18 years old
- ECOG PS score of 0 or 1
- Pathologically diagnosed as prostate adenocarcinoma
- High-risk patients
- No distant metastasis (clinical staging of M0) as determined by BICR of imaging examinations
- Subjects who are candidates for and plan to undergo radical prostatectomy (removal of the entire prostate and seminal vesicle plus pelvic lymphadenectomy)
Who cannot take part
- Subjects who received any prior treatment for prostate cancer, except medical ADT and/or first-generation androgen receptor antagonists (such as bicalutamide) for not more than 4 weeks
- Subjects who received any other investigational products or underwent major surgery within 4 weeks prior to randomization
- Subjects with dysphagia, chronic diarrhea, intestinal obstruction, or other factors affecting drug intake and absorption
- Subjects with a history of epilepsy, or diseases that can induce seizures occurred within 12 months prior to randomization (including a history of transient ischemic attack, stroke, traumatic brain injury, and cognitive impairment, requiring hospitalization)
- Subjects with active heart disease within 6 months prior to randomization, including: severe/unstable angina pectoris, myocardial infarction, symptomatic congestive heart failure, and ventricular arrhythmias requiring medical treatment
- Subjects who are planning bilateral orchidectomy during the treatment period of the study
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The study is being conducted to evaluate the efficacy and safety of SHR3680 plus androgen deprivation therapy (ADT) vs. placebo plus ADT in patients with high-risk localized or locally advanced prostate cancer using pathologic complete response (pCR) rate and metastasis-free survival (MFS).
The 2 groups in the trial
- Treatment group:SHR3680 + ADTTreatment being tested
Treatment: SHR3680
- Treatment group : Placebo + ADTPlacebo, for comparison
Treatment: Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase III Randomized, Placebo-Controlled, Double-Blind Study of SHR3680 Plus Androgen Deprivation Therapy (ADT) Versus ADT in Patients With High-Risk Localized or Locally Advanced Prostate Cancer Undergoing Radical Prostatectomy
- Record updated
- 3 April 2026